Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA054491-06
Application #
2095978
Study Section
Experimental Immunology Study Section (EI)
Project Start
1991-04-01
Project End
2001-01-31
Budget Start
1996-04-05
Budget End
1997-01-31
Support Year
6
Fiscal Year
1996
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Egilmez, Nejat K; Bankert, Richard B (2003) Liposome-mediated cytokine gene delivery to human tumor xenografts. Methods Enzymol 373:529-35
Hill, Hank C; Conway Jr, Thomas F; Sabel, Michael S et al. (2002) Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 62:7254-63
Bankert, Richard B; Hess, Stephen D; Egilmez, Nejat K (2002) SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions. Front Biosci 7:c44-62
Bankert, Richard B; Hess, Stephen D; Egilmez, Nejat K (2002) SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions. Front Biosci 7:c44-62
Sugano, M; Conway Jr, T F; Kelleher Jr, R J et al. (2001) Human dendritic cells pulsed with autologous Epstein-Barr virus transformed B-cell lymphoblastoid cell (BCL) lysate elicit a BCL specific MHC-class II restricted T-cell response. J Exp Clin Cancer Res 20:175-82
Bankert, R B; Egilmez, N K; Hess, S D (2001) Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol 22:386-93
Yamada, M; Shiroko, T; Kawaguchi, Y et al. (2001) CD40-CD40 ligand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM-1 and Fas expression and proliferation of human non-small cell lung tumors. Int J Cancer 92:589-99
Sugiyama, Y; Kato, M; Chen, F A et al. (2001) Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that depends on and is augmented by interleukin-12. J Immunother 24:37-45
Egilmez, N K; Jong, Y S; Sabel, M S et al. (2000) In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res 60:3832-7
Sugano, M; Egilmez, N K; Yokota, S J et al. (2000) Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 60:6942-9

Showing the most recent 10 out of 31 publications